MedTrace Logo

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

NCT05271630 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2026-03-02

No results posted yet for this study

Summary

The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).

Conditions

Interventions

OTHER

Autologous Stem Cell Transplant

This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT

DRUG

Immunomodulatory Agent

ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant

DRUG

Proteasome Inhibitor

ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant

Sponsors & Collaborators

  • Adaptive Biotechnologies

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Doris Hansen, MD · Moffitt Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-20
Primary Completion
2025-12-04
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05271630 on ClinicalTrials.gov